Immuneering (IMRX) to Release Earnings on Thursday

Immuneering (NASDAQ:IMRX) is anticipated to issue its Q4 2025 results before the market opens on Thursday, March 19th. Analysts expect the company to announce earnings of ($0.31) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, March 6, 2026 at 8:00 AM ET.

Immuneering (NASDAQ:IMRX) last released its quarterly earnings data on Friday, March 6th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.13. On average, analysts expect Immuneering to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Immuneering Stock Down 1.8%

Shares of IMRX stock opened at $4.96 on Tuesday. Immuneering has a twelve month low of $1.10 and a twelve month high of $10.08. The stock’s fifty day simple moving average is $5.07 and its 200 day simple moving average is $6.12. The firm has a market capitalization of $320.66 million, a P/E ratio of -3.59 and a beta of 0.46.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on IMRX. Weiss Ratings reissued a “sell (d-)” rating on shares of Immuneering in a research note on Monday, December 29th. Wall Street Zen raised Immuneering from a “sell” rating to a “hold” rating in a research note on Saturday, March 7th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $11.00 price objective on shares of Immuneering in a report on Monday, March 9th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $16.50.

Insider Buying and Selling at Immuneering

In other news, Director Peter Feinberg purchased 20,000 shares of the business’s stock in a transaction on Monday, January 12th. The shares were acquired at an average price of $4.35 per share, with a total value of $87,000.00. Following the completion of the transaction, the director owned 135,441 shares of the company’s stock, valued at $589,168.35. The trade was a 17.32% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Thomas J. Schall purchased 21,645 shares of the firm’s stock in a transaction on Thursday, January 15th. The shares were acquired at an average price of $4.67 per share, with a total value of $101,082.15. Following the completion of the acquisition, the director owned 74,530 shares in the company, valued at approximately $348,055.10. This trade represents a 40.93% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders purchased 51,819 shares of company stock worth $234,472. 22.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On Immuneering

Institutional investors and hedge funds have recently made changes to their positions in the business. Bank of America Corp DE grew its stake in Immuneering by 53.6% during the third quarter. Bank of America Corp DE now owns 43,754 shares of the company’s stock worth $306,000 after purchasing an additional 15,262 shares during the period. Corient Private Wealth LLC acquired a new position in Immuneering in the second quarter valued at approximately $215,000. EntryPoint Capital LLC bought a new position in shares of Immuneering during the 4th quarter worth approximately $206,000. LPL Financial LLC boosted its holdings in shares of Immuneering by 30.0% during the 4th quarter. LPL Financial LLC now owns 29,125 shares of the company’s stock worth $192,000 after buying an additional 6,725 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its position in shares of Immuneering by 46.4% during the 3rd quarter. Dimensional Fund Advisors LP now owns 19,562 shares of the company’s stock worth $137,000 after buying an additional 6,196 shares during the period. Institutional investors own 67.65% of the company’s stock.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.